Open this publication in new window or tab >>Show others...
2021 (English)In: Neonatology, ISSN 1661-7800, E-ISSN 1661-7819, Vol. 118, no 1, p. 18-27Article in journal (Refereed) Published
Abstract [en]
INTRODUCTION: Thrombocytopenia has been identified as an independent risk factor for retinopathy of prematurity (ROP), although underlying mechanisms are unknown. In this study, the association of platelet count and serum platelet-derived factors with ROP was investigated.
METHODS: Data for 78 infants born at gestational age (GA) <28 weeks were included. Infants were classified as having no/mild ROP or severe ROP. Serum levels of vascular endothelial growth factor A, platelet-derived growth factor BB, and brain-derived neurotrophic factor were measured in serum samples collected from birth until postmenstrual age (PMA) 40 weeks. Platelet counts were obtained from samples taken for clinical indication.
RESULTS: Postnatal platelet counts and serum concentrations of the 3 growth factors followed the same postnatal pattern, with lower levels in infants developing severe ROP at PMA 32 and 36 weeks (p < 0.05-0.001). With adjustment for GA, low platelet counts and low serum concentrations of all 3 factors at PMA 32 weeks were significantly associated with severe ROP. Serum concentrations of all 3 factors also strongly correlated with platelet count (p < 0.001).
CONCLUSION: In this article, we show that ROP, platelet counts, and specific pro-angiogenic factors correlate. These data suggest that platelet-released factors might be involved in the regulation of retinal and systemic angiogenesis after extremely preterm birth. Further investigations are needed.
Place, publisher, year, edition, pages
S. Karger, 2021
Keywords
Brain-derived neurotrophic factor, Platelet-derived growth factor, Platelets, Retinopathy of prematurity, Vascular endothelial growth factor
National Category
Pediatrics
Identifiers
urn:nbn:se:oru:diva-89829 (URN)10.1159/000512282 (DOI)000621523400001 ()33611321 (PubMedID)2-s2.0-85101760954 (Scopus ID)
Funder
Knut and Alice Wallenberg Foundation
Note
Funding Agencies:
Swedish Medical Research Council (SMRC) European Commission 2016-01131
Gothenburg Medical Society
ALF ALFGBG-717971
De Blindas Vänner, Kronprinsessan Margaretas Arbetsnämnd för synskadade
Cronqvists foundation
Örebro County Council Research Committee OLL-933343
United States Department of Health & Human Services National Institutes of Health (NIH) - USA EY017017 EY024868
BCH IDDRC 1U54HD090255 P01 HD18655
2021-02-242021-02-242021-04-27Bibliographically approved